Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: Differences between antibodies and TK inhibitors

References

• Aerts HJ, Dubois L, Perk L, Vermaelen P, van Dongen VA, Wouters BG, Lambin P. 2009. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. Journal of Nuclear Medicine 50:123–131.
   PubMed Web of Science ®Google Scholar
• Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh NT, Jackson S, Jackson C, Van Waes C. 2002. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. International Journal of Cancer 99:538–548.
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J, Kumar R. 1998. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. Journal of Biology and Chemistry 273:1568–1573.
   PubMed Web of Science ®Google Scholar
• Baumann M, Krause M, Dikomey E, Dittmann K, Dorr W, Kasten-Pisula U, Rodemann HP. 2007. EGFR-targeted anti-cancer drugs in radiotherapy: Preclinical evaluation of mechanisms. Radiotherapy Oncology 83:238–248.
   PubMed Web of Science ®Google Scholar
• Baumann M, Krause M, Hill R. 2008. Exploring the role of cancer stem cells in radioresistance. Nature Reviews Cancer 8:545–554.
   PubMed Web of Science ®Google Scholar
• Baumann M, Krause M, Zips D, Eicheler W, Dörfler A, Ahrens J, Petersen C, Brüchner K, Hilberg F. 2003. Selective inhibition of the epidermal growth factor tyrosine kinase by BIBX1382BS improves growth delay but not local control after fractionated irradiation in human FaDu squamous cell carcinoma in nude mice. International Journal of Radiation Biology 79:547–559.
   PubMed Web of Science ®Google Scholar
• Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W. 2007. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proceedings of the National Academy of Science USA 104:20932–20937.
   PubMed Web of Science ®Google Scholar
• Bean J, Riely GJ, Balak M, Marks JL, Ladanyi M, Miller VA, Pao W. 2008. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clinical Cancer Research 14:7519–7525.
   PubMed Web of Science ®Google Scholar
• Bertolini F, Chiara S, Bengala C, Antognoni P, Dealis C, Zironi S, Malavasi N, Scolaro T, Depenni R, Jovic G, Sonaglio C, Rossi A, Luppi G, Conte PF. 2009. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: A phase ii study in locally advanced rectal cancer. International Journal of Radiation Oncology Biology Physics 73:466–472.
   PubMed Web of Science ®Google Scholar
• Bianco R, Garofalo S, Rosa R, Damiano V, Gelardi T, Daniele G, Marciano R, Ciardiello F, Tortora G. 2008. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. British Journal of Cancer 98:923–930.
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. 2006. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. The New England Journal of Medicine 354:567–578.
   PubMed Web of Science ®Google Scholar
• Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton RF, Rowland Jr KM, Mischel P, Yong WH, Scheithauer BW, Schiff D, Giannini C, Buckner JC. 2008. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. Journal of Clinical Oncology 26:5603–5609.
   PubMed Web of Science ®Google Scholar
• Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. 2005. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. Journal of Clinical Oncology 23:8646–8654.
   PubMed Web of Science ®Google Scholar
• Caudell JJ, Sawrie SM, Spencer SA, Desmond RA, Carroll WR, Peters GE, Nabell LM, Meredith RF, Bonner JA. 2008. Locoregionally advanced head and neck cancer treated with primary radiotherapy: A comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. International Journal of Radiation Oncology Biology Physics 71:676–681.
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G. 2001. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clinical Cancer Research 7:1459–1465.
   PubMed Web of Science ®Google Scholar
• Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. 2006. Cancer Stem Cells – Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem Cells. Cancer Research 66:9339–9344.
   PubMedGoogle Scholar
• Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. 2004. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. The New England Journal of Medicine 351:337–345.
   PubMed Web of Science ®Google Scholar
• Czito BG, Willett CG, Bendell JC, Morse MA, Tyler DS, Fernando NH, Mantyh CR, Blobe GC, Honeycutt W, Yu D, Clary BM, Pappas TN, Ludwig KA, Hurwitz HI. 2006. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: Phase I trial results. Journal of Clinical Oncology 24:656–662.
   PubMed Web of Science ®Google Scholar
• Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L, Chen DJ, Kehlbach R, Rodemann HP. 2005a. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. Journal of Biology and Chemistry 280:31182–31189.
   PubMed Web of Science ®Google Scholar
• Dittmann K, Mayer C, Kehlbach R, Rodemann HP. 2008. Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. Molecular Cancer 7:69.
   PubMed Web of Science ®Google Scholar
• Dittmann K, Mayer C, Rodemann HP. 2005b. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiotherapy Oncology 76:157–161.
   PubMed Web of Science ®Google Scholar
• Eiblmaier M, Meyer LA, Watson MA, Fracasso PM, Pike LJ, Anderson CJ. 2008. Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines. Journal of Nuclear Medicine 49:1472–1479.
   PubMed Web of Science ®Google Scholar
• Eke I, Sandfort V, Mischkus A, Baumann M, Cordes N. 2006. Antiproliferative effects of EGFR tyrosine kinase inhibition and radiation-induced genotoxic injury are attenuated by adhesion to fibronectin. Radiotherapy Oncology 80:178–184.
   PubMed Web of Science ®Google Scholar
• Eke I, Sandfort V, Storch K, Baumann M, Roper B, Cordes N. 2007. Pharmacological inhibition of EGFR tyrosine kinase affects ILK-mediated cellular radiosensitization in vitro. International Journal of Radiation Biology 83:793–802.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Cantley LC. 2008. A sweet new role for EGFR in cancer. Cancer Cell 13:375–36.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA. 2007. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039–1043.
   PubMed Web of Science ®Google Scholar
• Fan Z, Masui H, Altas I, Mendelsohn J. 1993. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Research 53:4322–4328.
   PubMed Web of Science ®Google Scholar
• Friedmann BJ, Caplin M, Savic B, Shah T, Lord CJ, Ashworth A, Hartley JA, Hochhauser D. 2006. Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. Molecular Cancer Therapy 5:209–218.
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R, Janaskova T, Vansteenkiste J, Strausz J, Manikhas GM, Von Pawel J. 2007. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. Journal of Clinical Oncology 25:1545–1552.
   PubMed Web of Science ®Google Scholar
• Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MW, Rennie P, Fandi A, Johnson DH. 2004. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial – INTACT 1. Journal of Clinical Oncology 22:777–784.
   PubMed Web of Science ®Google Scholar
• Golding SE, Morgan RN, Adams BR, Hawkins AJ, Povirk LF, Valerie K. 2009. Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biology and Therapy 8:730–738.
   PubMed Web of Science ®Google Scholar
• Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG. 2009. A randomized phase iiib trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. Journal of Clinical Oncology 27:672–680.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH. 2004. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial – INTACT 2. Journal of Clinical Oncology 22:785–794.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA. 2005. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. Journal of Clinical Oncology 23:5892–5899.
   PubMed Web of Science ®Google Scholar
• Hu YP, Patil SB, Panasiewicz M, Li W, Hauser J, Humphrey LE, Brattain MG. 2008. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor. Cancer Research 68:8004–8013.
   PubMed Web of Science ®Google Scholar
• Huang SM, Harari PM. 2000. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clinical Cancer Research 6:2166–2174.
   PubMed Web of Science ®Google Scholar
• Huang SM, Li J, Armstrong EA, Harari PM. 2002. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Research 62:4300–4306.
   PubMed Web of Science ®Google Scholar
• Javle M, Pande A, Iyer R, Yang G, LeVea C, Wilding G, Black J, Nava H, Nwogu C. 2008. Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: Tissue effect predicts clinical response. American Journal of Clinical Oncology 31:329–334.
   PubMed Web of Science ®Google Scholar
• Kaplan O, Jaroszewski JW, Faustino PJ, Zugmaier G, Ennis BW, Lippman M, Cohen JS. 1990. Toxicity and effects of epidermal growth factor on glucose metabolism of MDA-468 human breast cancer cells. Journal of Biology and Chemistry 265:13641–13649.
   PubMedGoogle Scholar
• Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DH, Crowley DJ, Gandara DR. 2008. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. Journal of Clinical Oncology 26:2450–2456.
   PubMed Web of Science ®Google Scholar
• Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY. 2008. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 372:1809–1818.
   PubMed Web of Science ®Google Scholar
• Kong A, Calleja V, Leboucher P, Harris A, Parker PJ, Larijani B. 2008. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. PLoS ONE 3:e2881.
   PubMed Web of Science ®Google Scholar
• Krause M, Baumann M. 2008. Clinical biomarkers of kinase activity: Examples from EGFR inhibition trials. Cancer Metastasis Rev 27:387–402.
   PubMedGoogle Scholar
• Krause M, Hessel F, Zips D, Hilberg F, Baumann M. 2004. Adjuvant inhibition of the epidermal growth factor receptor after fractionated irradiation of FaDu human squamous cell carcinoma. Radiotherapy Oncology 72:95–101.
   PubMed Web of Science ®Google Scholar
• Krause M, Ostermann G, Petersen C, Yaromina A, Hessel F, Harstrick A, van der Kogel AJ, Thames HD, Baumann M. 2005a. Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. Radiotherapy Oncology 76:162–167.
   PubMed Web of Science ®Google Scholar
• Krause M, Prager J, Zhou X, Yaromina A, Dorfler A, Eicheler W, Baumann M. 2007. EGFR-TK inhibition before radiotherapy reduces tumour volume but does not improve local control: Differential response of cancer stem cells and nontumourigenic cells? Radiotherapy Oncology 83:316–325.
   PubMed Web of Science ®Google Scholar
• Krause M, Schutze C, Petersen C, Pimentel N, Hessel F, Harstrick A, Baumann M. 2005b. Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: A study on C225 in FaDu hSCC. Radiotherapy Oncology 74:109–115.
   PubMed Web of Science ®Google Scholar
• Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, Touge H, Makino H, Takata M, Miyata M, Nakamoto M, Burioka N, Shimizu E. 2007. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clinical Cancer Research 13:1552–1561.
   PubMed Web of Science ®Google Scholar
• Li L, Wang H, Yang ES, Arteaga CL, Xia F. 2008. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Research 68:9141–9146.
   PubMedGoogle Scholar
• Luo FR, Yang Z, Dong H, Camuso A, McGlinchey K, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S, Rose WC, Kramer RA, Wild R, Lee FY. 2005. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. Cancer Chemother Pharmacol 56:455–464.
   PubMedGoogle Scholar
• Machiels JP, Sempoux C, Scalliet P, Coche JC, Humblet Y, Van Cutsem E, Kerger J, Canon JL, Peeters M, Aydin S, Laurent S, Kartheuser S, Coster B, Roels S, Daisne JF, Honhon B, Duck L, Kirkove C, Bonny MA, Haustermans K. 2007. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Annales of Oncology 18:738–744.
   PubMed Web of Science ®Google Scholar
• Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F, Eguchi K, Takeda K, Inoue A, Tomii K, Harada M, Masuda N, Jiang H, Itoh Y, Ichinose Y, Saijo N, Fukuoka M. 2008. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. Journal of Clinical Oncology 26:4244–4252.
   PubMed Web of Science ®Google Scholar
• Maurel J, Martin-Richard M, Conill C, Sanchez M, Petriz L, Gines A, Miquel R, Gallego R, Cajal R, Ayuso C, Navarro S, Marmol M, Nadal C, Auge JM, Fernandez-Cruz L, Gascon P. 2006. Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics 66:1391–1398.
   PubMed Web of Science ®Google Scholar
• Milas L, Fang FM, Mason KA, Valdecanas D, Hunter N, Koto M, Ang KK. 2007. Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. International Journal of Radiation Oncology Biology Physics 67:568–572.
   PubMedGoogle Scholar
• Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. 2007. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 25:1960–1966.
   PubMed Web of Science ®Google Scholar
• Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY. 2007. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clinical Cancer Research 13:2795–803.
   PubMed Web of Science ®Google Scholar
• Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY. 2006. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of surviving expression counteract the antitumor action of erlotinib. Cancer Research 66:10100–11.
   PubMed Web of Science ®Google Scholar
• Mukherjee B, McEllin B, Camacho CV, Tomimatsu N, Sirasanagandala S, Nannepaga S, Hatanpaa KJ, Mickey B, Madden C, Maher E, Boothman DA, Furnari F, Cavenee WK, Bachoo RM, Burma S. 2009. EGFRvIII and DNA double-strand break repair: A molecular mechanism for radioresistance in glioblastoma. Cancer Research 69:4252–4259.
   PubMed Web of Science ®Google Scholar
• Nasu S, Ang KK, Fan Z, Milas L. 2001. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. International Journal of Radiation Oncology Biology Physics 51:474–477.
   PubMed Web of Science ®Google Scholar
• Nogueira-Rodrigues A, do Carmo CC, Viegas C, Erlich F, Camisao C, Fontao K, Lima R, Herchenhorn D, Martins RG, Moralez GM, Small IA, Ferreira CG. 2008. Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer. Clinical Cancer Research 14:6324–6329.
   PubMed Web of Science ®Google Scholar
• Pignon JP, Bourhis J, Domenge C, Designe L. 2000. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949–955.
   PubMed Web of Science ®Google Scholar
• Pignon JP, le Maitre A, Bourhis J. 2007. Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): An update. International Journal of Radiation Oncology Biology Physics 69:S112–114.
   PubMed Web of Science ®Google Scholar
• Rajput A, Koterba AP, Kreisberg JI, Foster JM, Willson JK, Brattain MG. 2007. A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo. Cancer Research 67:665–673.
   PubMedGoogle Scholar
• Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S, Carson 3rdWE. 2007. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clinical Cancer Research 13:6419–6428.
   PubMed Web of Science ®Google Scholar
• Rödel C, Arnold D, Hipp M, Liersch T, Dellas K, Iesalnieks I, Hermann RM, Lordick F, Hinke A, Hohenberger W, Sauer R. 2008. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. International Journal of Radiation Oncology Biology Physics 70:1081–1086.
   PubMed Web of Science ®Google Scholar
• Rodemann HP, Dittmann K, Toulany M. 2007. Radiation-induced EGFR-signaling and control of DNA-damage repair. International Journal of Radiation Biology 83:781–791.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L. 2005. Erlotinib in previously treated non-small-cell lung cancer. The New England Journal of Medicine 353:123–132.
   PubMed Web of Science ®Google Scholar
• Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kroning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris 3rd HA. 2008. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. Journal of Clinical Oncology 26:2311–2319.
   PubMed Web of Science ®Google Scholar
• Solomon B, Binns D, Roselt P, Weibe LI, McArthur GA, Cullinane C, Hicks RJ. 2005. Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging. Molecular Cancer Therapy 4:1417–1422.
   PubMedGoogle Scholar
• Steinbach JP, Klumpp A, Wolburg H, Weller M. 2004. Inhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia-induced cell death. Cancer Research 64:1575–1578.
   PubMedGoogle Scholar
• Stinchcombe TE, Morris DE, Lee CB, Moore DT, Hayes DN, Halle JS, Rivera MP, Rosenman JG, Socinski MA. 2008. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. Journal of Thoracic Oncology 3:250–257.
   PubMedGoogle Scholar
• Su H, Seimbille Y, Ferl GZ, Bodenstein C, Fueger B, Kim KJ, Hsu YT, Dubinett SM, Phelps ME, Czernin J, Weber WA. 2008. Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. European Journal of Nuclear Medicine and Molecular Imaging 35:1089–1099.
   PubMed Web of Science ®Google Scholar
• Swaisland H, Laight A, Stafford L, Jones H, Morris C, Dane A, Yates D. 2001. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clinical Pharmacokinetics 40:297–306.
   PubMed Web of Science ®Google Scholar
• Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K. 2005. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527–1537.
   PubMed Web of Science ®Google Scholar
• Thomas SM, Grandis JR. 2004. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treatment Review 30:255–268.
   PubMed Web of Science ®Google Scholar
• Toulany M, Baumann M, Rodemann HP. 2007. Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity. Molecular Cancer Research 5:863–872.
   PubMed Web of Science ®Google Scholar
• Toulany M, Dittmann K, Baumann M, Rodemann HP. 2005a. Radiosensitization of Ras-mutated human tumor cells in vitro by the specific EGF receptor antagonist BIBX1382BS. Radiotherapy Oncology 74:117–129.
   PubMed Web of Science ®Google Scholar
• Toulany M, Dittmann K, Kruger M, Baumann M, Rodemann HP. 2005b. Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway. Radiotherapy Oncology 76:143–150.
   PubMed Web of Science ®Google Scholar
• Ueda S, Basaki Y, Yoshie M, Ogawa K, Sakisaka S, Kuwano M, Ono M. 2006. PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib. Cancer Research 66:5346–5353.
   PubMedGoogle Scholar
• Valentini V, De Paoli A, Gambacorta MA, Mantini G, Ratto C, Vecchio FM, Barbaro B, Innocente R, Rossi C, Boz G, Barba MC, Frattegiani A, Lupattelli M, Doglietto GB. 2008. Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: A phase I and II Trial (1839IL/0092). International Journal of Radiation Oncology Biology Physics 72:644–649.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG. 2007. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Journal of Clinical Oncology 25:1658–1664.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R. 2008. Platinum-based chemotherapy plus cetuximab in head and neck cancer. The New England Journal of Medicine 359:1116–1127.
   PubMed Web of Science ®Google Scholar
• Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, Hung MC. 2008. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13:385–393.
   PubMed Web of Science ®Google Scholar
• Yamasaki F, Johansen MJ, Zhang D, Krishnamurthy S, Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K, Mills GB, Hortobagyi GN, Ueno NT. 2007. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Research 67:5779–5788.
   PubMed Web of Science ®Google Scholar
• Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi T, Yatabe Y, Nakamura T, Sone S. 2008. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Research 68:9479–9487.
   PubMed Web of Science ®Google Scholar